marketscreener.comOCT 51 min read

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

Original reporting

marketscreener.com

Published Oct 5, 2026, 7:41 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 5, 2026, 7:59 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefMarket movers

Primary signal

MARKET

Neutral

AI market analysis

Mentioned

$QURE

Relevance

7/10

AlphAI data visualization · based on marketscreener.com

Decision brief

The 30-second read

Med

Why it matters

The downgrade is the primary catalyst for the stock's decline, suggesting short‑term downside risk.

Market read

The downgrade is likely to influence intra‑day trading and may affect related biotech equities.

What to watch

Potential upcoming clinical data releases could offset short‑term sell‑off.

Relevance 7/10Novelty 6/10Timing: post-market today

Background

UniQure is a gene‑therapy company listed on NASDAQ. Barclays' downgrade reflects concerns about valuation and growth prospects.

Market effects

Sector

Biotech sector may see modest pullback as downgrade highlights valuation concerns.

Regional

US biotech stocks could face slight pressure in early trading.

Global

Limited to investors tracking gene‑therapy companies.

Counterpoint

What could challenge this read

Some investors may view the downgrade as an overreaction and look for a buying opportunity.

Key entities

company
UniQure
Gene‑therapy developer listed on NASDAQ (UQ).
analyst
Barclays
Equity research firm that issued the downgrade.

Read at source ← All news

OCT 8

$QUREHighAI 9/10

Is uniQure (QURE) Undervalued On New Huntingtons Data And FDA Filing Clarity?

uniQure (QURE) shares have fallen 48% in 30 days and 61.41% in 1 year, despite a 3x increase over 3 years. New Phase I/II data showed slowed Huntington's disease progression. Analysts debate if the stock is undervalued at $23.14, with fair value estimates ranging from $62.42 to $353.71, depending on future earnings and FDA approval.

simplywall.st2 min

OCT 7

$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

simplywall.st3 min

OCT 5

$QUREMed

QURE Downgraded by Barclays -- Price Target Lowered to $28.00

Barclays downgraded uniQure (QURE) from Overweight to Equal-Weight, lowering its price target from $60.00 to $28.00. The company's GF Value™ is $7.94, suggesting it's 195.5% overvalued. uniQure has a GF Score™ of 49/100, indicating mixed financial performance. Analysts cite concerns over financial health and market conditions.

gurufocus.com2 min

OCT 2

$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.

investing.com2 min

OCT 1

$QUREHighAI 8/10

uniQure (QURE) Reports New AMT 130 Data As FDA Opens Accelerated Review Path

uniQure (QURE) shared updated Phase I/II data for AMT-130, showing slowed Huntington’s disease progression. The FDA indicated 36-month high-dose data could support accelerated approval. The company focuses on gene therapies for rare conditions, with AMT-130 as a key catalyst.